Annual Report for FY 2024-25

Pat Growth 25pctEbitda Margin ExpansionRelated Party TransactionsResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹55.49

prior close

₹58.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%+2.4% vs market

Specialty Chemicals peers, median of 83sector+0.5%+2.2% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-6.0

10m

-2.0

15m

-2.0

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7+0.3+2.4+0.5+2.2

Next day

+1.3-0.4+1.7+0.1+1.2

+0.0-2.0+2.0-1.8+1.8

-1.5-1.5-0.0-1.6+0.2

-0.9-1.8+0.9-1.5+0.6

+0.2-2.9+3.1-3.1+3.3

-1.8-4.0+2.2-4.8+3.0

15d

-4.5-1.1-3.4-3.3-1.2

-5.8-3.1-2.8-4.7-1.2

-3.8-4.8+1.0-6.8+2.9

-5.2-0.7-4.5-6.5+1.3

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 83Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eiko Lifesciences has filed its 48th Annual Report for FY 2024-25 ahead of the AGM scheduled on 5th September 2025 via video conferencing. On a consolidated basis, the company posted revenue from operations of ₹3,249.18 lakhs, up over 16% year-on-year, while profit after tax nearly doubled to ₹174.08 lakhs. EBITDA margin improved from 6.4% to 9.46%, reflecting better operational control. The company also expanded into container leasing and logistics through a subsidiary (over 800 TEU containers deployed) and launched Eiko Scientific Solutions LLP for specialty chemicals R&D. Key resolutions at the AGM include re-appointment of directors, approval of material related party transactions, increase in authorized share capital from ₹14 crore to ₹20 crore, and appointment of a new Whole-Time Director.

Likely market impact

Shareholders should note the strong profit growth and EBITDA margin expansion as positives, while the increase in authorized share capital signals potential future fundraising. The material related party transaction resolution and appointment of a new Whole-Time Director are routine but worth monitoring for governance implications.